A Histone Acetyltransferase p300 Inhibitor C646 Induces Cell Cycle Arrest and Apoptosis Selectively in AML1-ETO-Positive AML Cells

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Gao, Xiao Ning ^a   Lin, Ji ^b   Ning, Qiao Yang ^a   Gao, Li ^a   Yao, Yu Shi ^a   Zhou, Ji Hao ^a   Li, Yong Hui ^a   Wang, Li Li ^a   Yu, Li ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; C 646; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE H3; PROTEIN BCL 2; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PERIPHERAL BLOOD STEM CELL;

ACETYLATION; ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HISTONES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, FUSION; P300-CBP TRANSCRIPTION FACTORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION;

EID: 84873504145     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055481     Document Type: Article

References (24)

1. Grisolano JL, O'Neal J, Cain J, Tomasson MH, (2003) An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A 100: 9506-9511.
2. Elagib KE, Goldfarb AN, (2007) Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation. Cancer Lett 251: 179-186.
3. Linggi B, Müller-Tidow C, van de Locht L, Hu M, Nip J, et al. (2002) The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 8: 743-750.
4. Fazi F, Racanicchi S, Zardo G, Starnes LM, Mancini M, et al. (2007) Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1-ETO oncoprotein. Cancer Cell 12: 457-466.
5. Wang L, Gural A, Sun XJ, Zhao X, Perna F, et al. (2011) The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 333: 765-769.
6. Giles RH, Peters DJ, Breuning MH, (1998) Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 14: 178-183.
7. Giordano A, Avantaggiati ML, (1999) p300 and CBP: partners for life and death. J Cell Physiol 181: 218-230.
8. Goodman RH, Smolik S, (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev 14: 1553-1577.
9. Chan HM, La Thangue NB, (2001) p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 114: 2363-2373.
10. Bandyopadhyay D, Okan NA, Bales E, Nascimento L, Cole PA, et al. (2002) Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res 62: 6231-6239.
11. Santer FR, Höschele PP, Oh SJ, Erb HH, Bouchal J, et al. (2011) Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther 10: 1644-1655.
12. Ait-Si-Ali S, Polesskaya A, Filleur S, Ferreira R, Duquet A, et al. (2000) CBP/p300 histone acetyl-transferase activity is important for the G1/S transition. Oncogene 19: 2430-2437.
13. Iyer NG, Xian J, Chin SF, Bannister AJ, Daigo Y, et al. (2007) p300 is required for orderly G1/S transition in human cancer cells. Oncogene 26: 21-29.
14. Kitabayashi I, Aikawa Y, Yokoyama A, Hosoda F, Nagai M, et al. (2001) Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. Leukemia 15: 89-94.
15. Katsumoto T, Yoshida N, Kitabayashi I, (2008) Roles of the histone acetyltransferasemonocytic leukemia zinc finger protein in normal and malignant hematopoiesis. Cancer Sci 99: 1523-1527.
16. Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, et al. (2010) Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol 17: 471-482.
17. Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, et al. (2006) A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 12: 945-949.
18. Fazi F, Zardo G, Gelmetti V, Travaglini L, Ciolfi A, et al. (2007) Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. Blood 109: 4432-4440.
19. Feng LX, Ravindranath N, Dym M, (2000) Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia. J Biol Chem 275: 25572-25576.
20. Wang YY, Zhao LJ, Wu CF, Liu P, Shi L, et al. (2011) C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A 108: 2450-2455.
21. Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD, (1996) The AML1-ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci U S A 93: 14059-14064.
22. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, et al. (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116: 354-365.
23. Ait-Si-Ali S, Polesskaya A, Filleur S, Ferreira R, Duquet A, et al. (2000) CBP/p300 histone acetyl-transferase activity is important for the G1/S transition. Oncogene 19: 2430-2437.
24. Chan HM, La Thangue NB, (2001) p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 114: 2363-2373.